Fresenius Kabi (Singapore) Pte Ltd. made an offer to acquire remaining 19.02% stake in Fresenius Kabi Oncology Ltd (BSE:532545) for INR 3.9 billion on April 16, 2013. Fresenius Kabi (Singapore) will acquire 30.06 million shares of Fresenius Kabi Oncology for INR 130 per share. The transaction was approved by the Board of Fresenius Kabi (Singapore). The transaction is subject to approval of Board of Directors and shareholders of Fresenius Kabi Oncology and regulatory ... approvals, consents, permissions and/or sanctions that may be required and subject to such conditions as may be prescribed by any of them while granting any such approval, consent, permission, or sanction. As on April 17, 2013, the Board of Directors of Fresenius Kabi Oncology approved the transaction. Bank of America Merrill Lynch acted as financial advisor for Fresenius SE & Co KGaA, parent of Fresenius Kabi AG.
Read More

Sponsored Financial Commentaries

To contact FRESENIUS KABI ONCOLOGY LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.